Pharmaceuticals & Biotechnology

Harmony Biosciences Holdings, Inc. CEO pay

Jeffrey M. Dayno, President and Chief. Fiscal year 2024, as reported to the SEC.

Total compensation

$7.1M

$7,145,170 for fiscal 2024: the Summary Compensation Table total, with stock and option awards at their grant-date value.

Definitive proxy statement, filed 2026-04-03SEC accession number 0001104659-26-039449

In context

The median chief executive among 21 Pharmaceuticals & Biotechnology companies with $500M – $1B in revenue was paid $7.1M. The middle half ranged from $3.5M to $14.5M.

Jeffrey M. Dayno's total is at that median.

See how your pay compares to Harmony Biosciences Holdings, Inc.'s peers

CEOSalary breaks this total into salary, bonus, stock and option awards, builds a peer set of comparable companies around it, and places your own package against them, with every figure cited to its filing.

Start a 3-day trial

Source: Harmony Biosciences Holdings, Inc.'s definitive proxy statement (SEC Form DEF 14A), Summary Compensation Table, fiscal year 2024. Figures are as reported by the company and are not adjusted or estimated. Context figures are from CEOSalary's snapshot of SEC filings as of 2026-10-28. Not financial, legal or compensation-consulting advice.